Literature DB >> 29270051

The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement.

A B K Abrahao1, S Karim2, B Colwell3, S Berry1, J Biagi4.   

Abstract

In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts.

Entities:  

Keywords:  Metastatic colorectal cancer; RAS wild-type; consensus statements; egfr monoclonal antibodies; predictive value; primary tumour location; prognostic value; tumour side

Year:  2017        PMID： 29270051      PMCID： PMC5736481          DOI： 10.3747/co.24.3757

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  34 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  The number of intraepithelial T cells decreases from ascending colon to rectum.

Authors:  J A Kirby; M Bone; H Robertson; M Hudson; D E J Jones
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

3.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Authors:  S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin
Journal:  Eur J Cancer       Date:  2015-05-12       Impact factor: 9.162

Review 4.  Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location.

Authors:  J A Bufill
Journal:  Ann Intern Med       Date:  1990-11-15       Impact factor: 25.391

5.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Authors:  Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann
Journal:  Eur J Cancer       Date:  2016-11-29       Impact factor: 9.162

6.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Authors:  Niall C Tebbutt; Kate Wilson; Val J Gebski; Michelle M Cummins; Diana Zannino; Guy A van Hazel; Bridget Robinson; Adam Broad; Vinod Ganju; Stephen P Ackland; Garry Forgeson; David Cunningham; Mark P Saunders; Martin R Stockler; Yujo Chua; John R Zalcberg; R John Simes; Timothy J Price
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Authors:  Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

8.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Authors:  Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Journal:  Lancet Oncol       Date:  2009-11-26       Impact factor: 41.316

9.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Authors:  Sabine Tejpar; Sebastian Stintzing; Fortunato Ciardiello; Josep Tabernero; Eric Van Cutsem; Frank Beier; Regina Esser; Heinz-Josef Lenz; Volker Heinemann
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

10.  Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma.

Authors:  P G Rothberg; J M Spandorfer; M D Erisman; R N Staroscik; H F Sears; R O Petersen; S M Astrin
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640
View more
  4 in total

1.  Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.

Authors:  W W L Wong; M Zargar; S R Berry; Y J Ko; M Riesco-Martínez; K K W Chan
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 2.  Current and emerging biomarkers in metastatic colorectal cancer.

Authors:  M K C Lee; J M Loree
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

3.  Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.

Authors:  D Gwyn Bebb; Shantanu Banerji; Normand Blais; Patrice Desmeules; Sharlene Gill; Andrea Grin; Harriet Feilotter; Aaron R Hansen; Martin Hyrcza; Monika Krzyzanowska; Barbara Melosky; Jonathan Noujaim; Bibiana Purgina; Dean Ruether; Christine E Simmons; Denis Soulieres; Emina Emilia Torlakovic; Ming-Sound Tsao
Journal:  Curr Oncol       Date:  2021-01-15       Impact factor: 3.677

Review 4.  Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives.

Authors:  Rodrigo Motta; Santiago Cabezas-Camarero; Cesar Torres-Mattos; Alejandro Riquelme; Ana Calle; Alejandro Figueroa; Miguel J Sotelo
Journal:  J Clin Transl Res       Date:  2021-08-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.